Cancer Causes & Control

, Volume 21, Issue 11, pp 1851–1856 | Cite as

Factors associated with Type I and Type II endometrial cancer

  • Ashley S. Felix
  • Joel L. Weissfeld
  • Roslyn A. Stone
  • Robert Bowser
  • Mamatha Chivukula
  • Robert P. Edwards
  • Faina Linkov
Original paper



We investigated risk factors for Type II (n = 176) vs. Type I (n = 1,576) endometrial cancer (EC) in cases treated at Magee-Womens Hospital between 1996 and 2008.


Clinical data were available from the University of Pittsburgh Medical Center (UPMC) Network Cancer Registry. Logistic regression was used to estimate the adjusted odds of having Type II EC vs. Type I EC. Risk factors of interest in this analysis were age, race, body mass index (BMI), year of diagnosis, parity, menopausal status, and history of additional primary tumors.


Relative to women with Type I EC, women with Type II EC were more likely to be older at diagnosis (OR: 1.03 per 1 year increase in age, 95% CI 1.01–1.05), of non-white race (OR: 2.95, 95% CI 1.66–5.27), have a history of additional primary tumors (OR: 1.56, 95% CI 1.05–2.32), and less likely to be obese (OR: 0.45, 95% CI 0.29–0.70).


In this large retrospective cohort of patients with EC, the striking difference in risk factors associated with Type II vs. Type I tumors suggests that these subtypes represent different disease entities that require different treatment modalities. Currently, Type II cases have a significantly worse prognosis compared to Type I. Further characterization of risk factors associated with developing Type II tumors is needed to prevent this aggressive malignancy.


Endometrial cancer Epidemiology Type I Type II 



We wish to thank the University of Pittsburgh Medical Center (UPMC) Registry Information Services (RIS) team, especially Sharon Winters and Louise Mazur, for their help with procuring the data for this study as well as explaining technical details regarding the registry.


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249CrossRefPubMedGoogle Scholar
  2. 2.
    Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH (2007) Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol 62(1):28–34 discussion 5–6CrossRefPubMedGoogle Scholar
  3. 3.
    Sorosky JI (2008) Endometrial cancer. Obstet Gynecol 111(2 Pt 1):436–447PubMedGoogle Scholar
  4. 4.
    Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A et al (2008) Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 198(2):218 e1-e6CrossRefPubMedGoogle Scholar
  5. 5.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130CrossRefPubMedGoogle Scholar
  6. 6.
    Adami HO (ed) (2008) Textbook of cancer epidemiology. Oxford University Press Inc, New YorkGoogle Scholar
  7. 7.
    Lauchlan SC (1981) Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 105(11):615–618PubMedGoogle Scholar
  8. 8.
    Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6(2):93–108CrossRefPubMedGoogle Scholar
  9. 9.
    Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17CrossRefPubMedGoogle Scholar
  10. 10.
    Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S et al (2008) Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 108(3–5):221–229CrossRefPubMedGoogle Scholar
  11. 11.
    Ryan AJ, Susil B, Jobling TW, Oehler MK (2005) Endometrial cancer. Cell Tissue Res 322(1):53–61CrossRefPubMedGoogle Scholar
  12. 12.
    Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS (2008) Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 168(6):563–570 discussion 71–76CrossRefPubMedGoogle Scholar
  13. 13.
    Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ (2007) Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 26(2):103–114CrossRefPubMedGoogle Scholar
  14. 14.
    Lacey JV Jr, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB et al (2008) Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 113(8):2073–2081CrossRefPubMedGoogle Scholar
  15. 15.
    Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11(12):1531–1543PubMedGoogle Scholar
  16. 16.
    Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88(4):814–824CrossRefPubMedGoogle Scholar
  17. 17.
    Yi X, Zheng W (2008) Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol 20(1):20–25CrossRefPubMedGoogle Scholar
  18. 18.
    Dunton CJ, Balsara G, McFarland M, Hernandez E (1991) Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv 46(2):97–102CrossRefPubMedGoogle Scholar
  19. 19.
    Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O’Malley DM et al (2009) An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 115(2):244–248CrossRefPubMedGoogle Scholar
  20. 20.
    Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA et al (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94(5):642–646PubMedGoogle Scholar
  21. 21.
    Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS et al (1999) Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74(3):385–394CrossRefPubMedGoogle Scholar
  22. 22.
    Petignat P, Usel M, Gauthier P, Popowski Y, Pelte MF, Bouchardy C et al (2008) Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. Eur J Gynaecol Oncol 29(1):57–60PubMedGoogle Scholar
  23. 23.
    Sagr ER, Denschlag D, Kerim-Dikeni A, Stanimir G, Gitsch G, Gilbert L (2007) Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. Anticancer Res 27(2):1213–1217PubMedGoogle Scholar
  24. 24.
    Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB (2009) Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 115(1):142–153CrossRefPubMedGoogle Scholar
  25. 25.
    Mendivil A, Schuler KM, Gehrig PA (2009) Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 16(1):46–52PubMedGoogle Scholar
  26. 26.
    UPMC. UPMC Cancer Center Centers Registry Information Services. Pittsburgh: Department of Biomedical Informatics; 2009 (updated 2009; cited 2009 8/28/2009); Available from:
  27. 27.
    Linkov F, Taioli E (2008) Factors influencing endometrial cancer mortality: the Western Pennsylvania Registry. Future Oncol 4(6):857–865CrossRefPubMedGoogle Scholar
  28. 28.
    Sherman ME, Bur ME, Kurman RJ (1995) p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26(11):1268–1274CrossRefPubMedGoogle Scholar
  29. 29.
    CDC. Healthy weight–it’s not a diet it’s a lifestyle. 2009 (updated 2009; cited 2009 Sep 29, 2009); Available from:
  30. 30.
    Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, Duska LR et al (2007) Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31(7):979–987CrossRefPubMedGoogle Scholar
  31. 31.
    Bjorge T, Engeland A, Tretli S, Weiderpass E (2007) Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 120(2):378–383CrossRefPubMedGoogle Scholar
  32. 32.
    Boruta DM 2nd, Gehrig PA, Groben PA, Bae-Jump V, Boggess JF, Fowler WC Jr et al (2004) Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 101(10):2214–2221CrossRefPubMedGoogle Scholar
  33. 33.
    Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS et al (2000) The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77(1):55–65CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Ashley S. Felix
    • 1
    • 2
  • Joel L. Weissfeld
    • 1
    • 2
  • Roslyn A. Stone
    • 3
  • Robert Bowser
    • 4
  • Mamatha Chivukula
    • 5
  • Robert P. Edwards
    • 6
  • Faina Linkov
    • 1
    • 2
  1. 1.Division of Cancer Prevention and Population ScienceUniversity of Pittsburgh Cancer InstitutePittsburgh15232USA
  2. 2.Department of EpidemiologyUniversity of Pittsburgh Graduate School of Public HealthPittsburghUSA
  3. 3.Department of BiostatisticsUniversity of Pittsburgh Graduate School of Public HealthPittsburghUSA
  4. 4.Department of PathologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  5. 5.Department of PathologyMagee-Womens Hospital of UPMC Health SystemPittsburghUSA
  6. 6.Department of Obstetrics and Gynecologic OncologyMagee-Womens Hospital of UPMC Health SystemPittsburghUSA

Personalised recommendations